Todd J. Leon

On April 23, 2026, the United States Department of Justice and Drug Enforcement Administration announced an order reclassifying certain marijuana products from Schedule I to Schedule III under the Federal Controlled Substances Act. This move represents the most significant shift in federal cannabis policy in decades. While much of the public discussion thus far has focused on the tax and criminal implications of the change, there are more nuanced questions for insurers – particularly in the context of homeowners policies and the enforceability of exclusions for “controlled dangerous substances.”

The Regulatory Shift

For decades, marijuana was classified as a Schedule I drug under the Controlled Substances Act. That classification, on a tier reserved for substances with no accepted medical use and a high potential for abuse, aligned marijuana with substances like heroin, LSD and peyote. The April 2026 order altered that framework by recognizing that FDA-approved products containing marijuana and marijuana products regulated by a state medical marijuana license will be reclassified in Schedule III of the Controlled Substances Act. This move indicates at least some level of federal recognition that state-licensed marijuana has accepted medical uses and a lower potential for abuse. 

Importantly, the change is limited. The reclassification does not federally legalize marijuana, and recreational cannabis generally remains a Schedule I substance. This bifurcated treatment of medical versus recreational marijuana use will likely become central to future discussions, including insurance coverage litigation.

Implications for Homeowners Policies

Most standard homeowners policies contain exclusions for losses “arising out of” the use, sale, manufacture, delivery, transfer or possession of controlled substances, as defined by the Federal act. Notably, the standard “controlled substances” exclusion in policies specifically references cocaine, LSD, marijuana and narcotic drugs.

The rescheduling of marijuana to Schedule III raises the key question of how or whether the “controlled substances” exclusion will continue to apply. At this point, the answer to this question appears to be that the provision will continue to preclude coverage for losses arising out of marijuana claims, since Schedule III substances remain “controlled substances” under federal law and marijuana remains listed, by name, in the exclusion. To be clear, the reclassification does not remove marijuana from the statutory framework; it merely places marijuana in a less restrictive category of the Controlled Substances Act.

Moving forward, insurers will likely argue that the plain language of the exclusion means that the provision continues to apply. For their part, policyholders may begin to push back on that interpretation, particularly in jurisdictions like Pennsylvania and New Jersey, where legalized cannabis regimes are well-established. The argument will be that conduct authorized by state law, and now partially recognized at the federal level, should not trigger exclusions designed to address criminal or inherently hazardous activity. Ultimately, any coverage disputes will likely turn on traditional principles of policy interpretation: plain meaning, ambiguity, and the reasonable expectations of the insured. Courts in Pennsylvania and New Jersey, both of which have robust bodies of insurance coverage law, will play an important role in shaping how these disputes are resolved.

Conclusion

The move of FDA-approved drug products containing marijuana and medicinal marijuana products subject to a qualifying state-issued license to Schedule III is an important step in federal drug policy, but its immediate impact on homeowners insurance is limited. Simply put, marijuana remains a controlled substance, such that standard exclusions to homeowners policies should continue to apply. Moving forward, the most significant effects of the change in classification will emerge in close cases, particularly in states like New Jersey where recreational and medical marijuana is legal (at least to some degree) under state law. For now, the change creates more questions than answers. Those questions, which are likely to be centered on policy language, legality, and causation, are likely to shape the next wave of coverage litigation in this area.